• DuPont de Nemours recently reported that its U.S. healthcare manufacturing operations are now supplied entirely by renewable electricity via additional Renewable Energy Certificates, while its MemCor membrane bioreactor technology was chosen to upgrade Sydney’s Riverstone Water Resource Recovery Facility.
• Together, these moves highlight how DuPont is tying its healthcare and water businesses more closely to decarbonization and clean-infrastructure spending, potentially reinforcing its long-term role in sustainability-focused markets.
• We’ll now examine how DuPont’s full renewable power shift in U.S. healthcare manufacturing may influence its existing investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

DuPont de Nemours Investment Narrative Recap

To own DuPont today, you generally need to believe its pivot toward healthcare, water, and specialty materials can offset legacy risks like PFAS liabilities and portfolio shrinkage after spin offs. The move to 100 percent renewable electricity in U.S. healthcare manufacturing and the MemCor win in Sydney support the healthcare and water growth story, but they do not materially change near term earnings volatility or legal overhangs that remain central to the thesis.

Among recent announcements, DuPont’s reaffirmed 2026 sales guidance of about US$7.08 billion to US$7.14 billion stands out, because it frames how investors may view sustainability news. The renewable power shift and Riverstone project can be seen in the context of management’s effort to support more stable growth from Healthcare & Water, even as the company manages PFAS litigation, spin off complexity, and pricing pressure in its more cyclical industrial businesses.

Yet alongside this progress, investors should also be aware of the ongoing PFAS legal exposure and how future state level actions could still...

DuPont de Nemours' narrative projects $14.0 billion revenue and $1.7 billion earnings by 2028. This requires 3.7% yearly revenue growth and roughly a $1.6 billion earnings increase from $71.0 million today.

Uncover how DuPont de Nemours' forecasts yield a $56.12 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming DuPont’s revenue would reach only about US$7.6 billion and earnings about US$814.4 million by 2029, so if you are weighing today’s sustainability wins against that earlier outlook, it is worth remembering how differently people can view the same company and exploring how this new information might shift those more pessimistic expectations.

Explore 4 other fair value estimates on DuPont de Nemours - why the stock might be worth just $50.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DuPont de Nemours research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DuPont de Nemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DuPont de Nemours' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.